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Abstract 
Therapeutic angiogenesis is a major goal of regenerative medicine, but no clinically approved small 
molecule exists that enhances new blood vessel formation. Here we show, using a phenotype-driven 
high-content imaging screen of an annotated chemical library of 1280 bioactive small molecules, that the 
retinoid agonist Tazarotene, enhances in vitro angiogenesis, promoting branching morphogenesis, and 
tubule remodeling. The pro-angiogenic phenotype is mediated by Retinoic Acid Receptor (RAR) but not 
Retinoic X Receptor (RXR) activation, and is characterized by secretion of the pro-angiogenic factors 
Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor (VEGFA), Plasminogen 
Activator, Urokinase (PLAU) and Placental Growth Factor (PGF), and reduced secretion of the anti-
angiogenic factor Pentraxin-3 (PTX3) from adjacent fibroblasts. In vivo, Tazarotene enhanced the 
growth of mature and functional microvessels in Matrigel implants and wound healing models, and 
increased blood flow. Notably, in ear punch wound healing model, Tazarotene promoted tissue repair 
characterized by rapid ear punch closure with normal-appearing skin containing new hair follicles, and 
maturing collagen fibers. Our study suggests that Tazarotene, an FDA-approved small molecule, could 
be potentially exploited for therapeutic applications in neovascularization and wound healing. 
 
Keywords: High content screening, Tazarotene, Retinoic acid, Endothelial cell, Angiogenesis, Wound 
healing 
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Introduction 
Angiogenesis, the growth of new vessels from pre-existing ones, plays a critical role in tissue renewal 
and repair. Insufficient angiogenic response occurs in diseases, such as ischemic heart disease, 
peripheral arterial disease, Alzheimer’s disease, ulcers, and chronic wound healing causing dysfunction 
of repair and regeneration1-3. Currently no clinically approved small molecule exists that enhances new 
blood vessel formation.  Clinical efforts to develop pro-angiogenic therapies have largely focused on 
administration of single pro-angiogenic growth factors such as VEGF and FGF using recombinant 
protein or gene transfer technologies4,5, but these are currently viewed as being only modestly 
successful6, possibly because therapeutically beneficial levels of growth factor are not achieved7, or that 
the cooperative molecular interactions necessary for the establishment of a functional vascular network 
are not achieved through a single growth factor8, or indeed that such complex molecular interactions and 
therapeutic targets are only partially understood. 
Phenotype-driven approaches can overcome this knowledge gap by minimizing assumptions regarding 
molecular interactions and targets and instead focusing directly on functional aspects of vascular 
network formation9. The unbiased identification of therapeutically active molecules using direct 
phenotypic screens is now possible using high-content microscopy and image analysis algorithms to 
generate quantitative phenotypic data10. Provided an appropriate in vitro model of in vivo angiogenesis is 
used, such phenotype-driven screens could identify pro-angiogenic molecules that could be 
therapeutically translated.   
The growth of new functional blood vessel network is determined by the extent of branching and 
tubulogenesis. The endothelial tube formation assay recapitulates most cellular process involves in the 
assembly of endothelial cells into a primary plexus (e.g. cell-cell, cell-matrix interaction) and has a high 
predictive value for angiogenesis-related cellular morphogenesis such as vascular branching and, 
suggesting that this is an appropriate model for in vivo angiogenesis11,12. We developed a high content 
imaging approach using the endothelial tube formation assay to screen small molecule libraries with aim 
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of identifying novel therapeutic molecules that enhance new blood vessel growth. Here, we identify and 
characterize Tazarotene, a small molecule that promotes endothelial tubulogenesis and branching. We 
also demonstrate that systemic delivery of Tazarotene stimulates functional neovascularization and 
accelerates wound healing. 
 
Results 
High content screen of small molecule library using endothelial tube formation assay  
The endothelial tube formation assay is quantifiable, rapid, and reproducible, and measures key features 
of angiogenesis such as branching and tubulogenesis13 14. We miniaturized the assay to a 384-well plate 
format, and established a Z’ factor (a statistical measure of assay robustness) for total tube length of 
0.33, which is acceptable for high-throughput cell-based screening (Supplementary Fig. 1). To identify 
small molecules capable of enhancing endothelial tube formation, we screened a Library Of 1280 
Pharmacologically Active Compounds (LOPAC) in a 384-well plate format at a final compound 
concentration of 10 µM. Primary screening of the LOPAC library included four 384-well plates with a 
Z’ factor of 0.48 ±0.13 and a hit rate of 1.1% for tube formation enhancers and 6.2% for inhibitors 
(Supplementary Fig. 2a, Fig. 1). As branching points and total tube length were positively correlated 
(Supplementary Fig. 2b), we used total tube length as the parameter for hit selection, using a B-score 
threshold >+2.6 and <-4 for identifying enhancers and inhibitors respectively. The screen resulted in an 
initial active compound list of 79 inhibitors and 15 enhancers (Supplementary Table 1 & 2). One 
enhancer hit was excluded from the list after visual examination of the well images because of a 
technical artifact. We re-assayed the 14 enhancers using three independent five-point dose dependence 
trials (1.25 µM to 20 µM) in 96-well plates using the same image analysis algorithm used in the primary 
screen. Three compounds increased significantly and consistently the total tube length by more that 15% 
over the negative control (Fig. 2a). To re-confirm the results of the screen, we re-examined three active 
lead compounds in an independent organotypic assay for angiogenesis, in which fibroblasts were co-
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cultured with endothelial cells (Fig. 2b). We found that the dopamine re-uptake inhibitor (GBR-12909) 
reduced tubulogenesis and branching whereas the P38 kinase inhibitor (SB202190) modestly increased 
the tubulogenesis and branching. The retinoid agonist Tazarotene showed a robust pro-angiogenic 
activity reflected by around 60% increase in total tube length and branching points compared to controls, 
and was therefore followed-up further. 
 
Tazarotene promotes endothelial tube remodeling and branching 
Tazarotene is a synthetic third generation retinoid that is approved by the US Food and Drug 
Administration for the topical treatment of plaque psoriasis and acne vulgaris15. We measured the EC50 
of Tazarotene (concentration required to enhance the total tube length by 50%) in the organotypic 
angiogenesis assay. The EC50 of Tazarotene (800 nM) in this assay is comparable to the EC50 of other 
retinoids in cell-based phenotypic assays16, suggesting that enhancement of endothelial tube formation 
was unlikely to be an off-target effect (Fig. 2c). We observed a distinctive pattern of the organotypic 
vascular-like network after treatment of Tazarotene, characterized by highly branched, thinner tubes, 
minimal cell clustering, and increased filopodia formation in the lateral sides of outgrowing endothelial 
tubes (Fig. 2d). The increase in branching triggered by Tazarotene was noted from 3 days following 
endothelial cell seeding onto fibroblasts (the early phase of network formation) (Supplementary Fig. 
3a). To evaluate the behavior of the newly forming endothelial tubes following Tazarotene treatment, 
we traced GFP-expressing HUVECs in co-culture by live cell imaging in the initial phase of network 
formation. Control endothelial cells initially form clusters with minimal remodeling and branch 
formation at this stage (Supplementary Fig. 3b). In contrast, with Tazarotene treatment, endothelial 
cells elongated and sprouted, and endothelial tubes remodeled more rapidly than controls, becoming 
thinner with time (Supplementary Fig. 3b). However, Tazarotene did not affect endothelial cell 
motility in single cell culture or in co-culture measured over 24 hours (Supplementary Fig. 4). 
VEGFR2 & VEGFR3 expression is very low or absent in most adult blood vessels, but expression is up-
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regulated in angiogenic endothelial cells and in endothelial tip cells17,18. We therefore investigated 
VEGFR2 & VEGFR3 expression in cultured endothelial cells after Tazarotene treatment, and found that 
it augmented VEGFR3 but not VEGFR2 expression (Fig 2e). Taken together, these findings show that 
Tazarotene induces sprouting behavior of endothelial cells and tubule remodeling. 
 
Tazarotene promotes angiogenesis via retinoic acid receptor activation 
The biologically active form tazarotenic acid is produced by esterase hydrolysis of tazarotene in the 
skin, and binds to three members of the RAR family of retinoid nuclear receptors, with relatively more 
selectivity for RARβ and RARγ19. We therefore investigated whether the observed pro-angiogenic effect 
of tazarotene is mediated via retinoic acid signaling. We used a pharmacological rather than a genetic 
approach here as combinatorial isoform specific siRNA for the many retinoid receptor isoforms is 
technically challenging. To quantify angiogenesis in the experiment set, we measured multiple 
parameters depicting the vascular-like network in the organotypic angiogenesis assay after different 
treatments. We then hierarchically clustered the compounds into distinct angiogenic phenotypes based 
on four angiogenic parameters: total tube length, branching points, tube thickness and total node area. 
All-trans-retinoic-acid (ATRA) exhibited the most similar pro-angiogenic phenotype to Tazarotene, 
suggesting that effects are via the canonical pathway (Fig. 3a). Similar effects were observed using 9-
cis-retinoic acid, which is an intracellular product of ATRA isomerization, confirming the effects of 
Tazarotene through activation of RAR (Fig. 3a). While the selective pan RXR agonist (SR 11237) 
slightly increased total tube length and branching, endothelial tubes were thicker with greater cell 
clustering (nodes), unlike the Tazarotene- or ATRA-induced phenotypes (Fig. 3a). We next examined 
the effect of isoform selective RAR agonists20,21. We found that selectvie RARβ or RARγ agonists 
(CD2314 and BMS961 respectively) reproduced the distinct pro-angiogenic phenotype of Tazarotene. 
The selective RARα agonist (BMS 753) increased overall tube formation to a lesser extent than RARβ 
or RARγ agonists (Fig. 3a). As a complementary approach, we also examined the effect of RAR and 
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RXR blockade on Tazarotene-induced angiogenesis. The addition of the pan-retinoic acid receptor 
inverse agonist (BMS493) attenuated the ability of Tazarotene to enhance the angiogenesis. In contrast, 
the incubation of Tazarotene with an RXR antagonist (UVI3003)22 did not affect the pro-angiogenic 
phenotype of Tazarotene (Fig. 3b). These data clearly indicate that the effect of Tazarotene on the 
branching tubule remodeling is only mediated through RAR binding. We next investigated the effect of 
Liarozole, a retinoic acid metabolic blocking agent that inhibits the cytochrome P450 (CYP26A1)-
dependent catabolism of retinoic acid, thereby increasing intracellular retinoic acid23. Liarozole 
treatment induced the tube formation and increased endothelial branching compared to controls (Fig. 
3c). We next examined the expression of RARRES1, a specific downstream target gene for retinoic 
signaling activation24. Tazarotene induced RARRES1 mRNA expression 6-fold in endothelial cells and 
40-fold in fibroblasts (Fig. 3d). Taken together these data indicate that the pro-angiogenic effect of 
Tazarotene is through the canonical retinoic acid-signaling pathway via RAR and not RXR activation.  
 
Tazarotene enhances the pro-angiogenic paracrine effects of fibroblasts  
Given the known link between cell growth and angiogenesis, we next evaluated cell proliferation 
following Tazarotene treatment. When endothelial cells were cultured alone, their cell numbers (as 
measured by DAPI) were decreased slightly after treatment with Tazarotene doses up to 10 µfgM but the 
decrease was more pronounced at 20 µM. The level of DNA synthesis (as measured by EdU 
incorporation) did not change significantly (Fig. 4a). In the organotypic angiogenesis co-culture 
experiments, endothelial cells were stained with anti-CD31 antibody and subsequently the total cell 
number and percentage of EdU-positive cells were quantified in both endothelial cells (CD31+) and 
fibroblasts (CD31-). We found that Tazarotene treatment did not affect either endothelial or fibroblast 
cell numbers significantly, at doses up to 10 µM, but reduced fibroblast cell numbers at 20 µM. We also 
observed an increase in DNA synthesis of fibroblasts at doses from 1-10 µM (Fig. 4b). Thus there does 
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not appear to be a significant effect of Tazarotene on endothelial cell number or DNA synthesis when 
they are co-cultured with fibroblasts.   
As retinoic acid can induce vascular growth factors such as VEGF and HGF25,26, we next explored the 
effect of Tazarotene on the secretion of angiogenesis-related factors profile from fibroblasts. Using a 
comparative proteome profiler array of 55 different cytokines we found that Tazarotene increased the 
secretion of the vascular growth factors VEGFA, HGF, PGF and PLAU27) whereas the secretion of 
PTX3, an inhibitor of angiogenesis28 was decreased (Fig. 4c). We found that Tazarotene up regulated 
PGF mRNA expression, whereas PTX3 mRNA expression was decreased (Fig. 4d). Furthermore, we 
validated the enhanced secretion of PGF and PTX3 by ELISA (Fig. 4e). These data suggest that the pro-
angiogenic effect of Tazarotene is more pronounced in the co-culture angiogenesis model partly because 
of paracrine effects, which amplify the angiogenic response. 
 
Tazarotene stimulates in vivo functional neovascularization 
To investigate whether systemically administered Tazarotene enhanced in vivo neovascularization, we 
tested its efficacy in Matrigel implants implanted in mice. Intra-peritoneal administration of Tazarotene 
was well tolerated (Supplementary Fig. 5) and resulted in enhanced expression of hepatic RARRES1 (a 
retinoid pathway target22) indicating that Tazarotene was systemically bioactive (Supplementary Fig. 
6). The invasion and the growth of microvessels into the Matrigel implant was quantified by CD31 and 
-smooth muscle (SM) actin staining of endothelium and mural cells, and was significantly higher 
following systemic Tazarotene. Moreover, the neovessels formed appeared more mature and covered by 
mural cells (α-SM actin positive cells) (Fig. 5b). We quantified neovessel perfusion by perfusing mice 
with Microfil, and imaged dissected plugs using microCT. Microvessels penetrating the Matrigel 
implant are more abundant in the Tazarotene treated group (7-folds versus control) and invading 
neovessels penetrate deeper into the gel (Fig. 5c). To visualize the structure and perfusion of 
microvasculature at a cellular level, we perfused mice with biotinylated-isolectinB4. Thick section 
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preparations of Matrigel revealed that Tazarotene increased the formation of microvessels with an 
enhanced capacity to receive flow whereas fewer microvessels could be identified in control mice (Fig. 
5d). 
 
Tazarotene enhances wound vascularization and healing  
Angiogenesis is a critical part of the normal healing process. New blood vessels deliver oxygen, 
nutrients, and essential growth factors to injured tissues29. To assess its effect on wound angiogenesis, 
first we used an ear punch wound model. The ear punch model is an established model of wound healing 
model and has been widely used to study wound healing, tissue regeneration, innervation and 
neovascularization 30, 31, 32, 33. In particular, quantitative analysis of new vessel formation and wound 
morphometry is feasible in this model. Tazarotene was injected intra-peritoneallly for six days following 
injury. The group treated with Tazarotene showed a remarkable acceleration of wound closure measured 
after 12 days (Fig. 6a). Blood flow and tissue perfusion was measured by contrast speckle laser imaging 
at 6 and 12 days following injury and was significantly enhanced in the regenerating area of the 
Tazarotene-treated group (Fig. 6b). Histologically, a major difference in ear hole size with neogenesis of 
hair follicles (Fig. 6c, Supplementary Fig. 7) was apparent at the wound margins by day 14 after 
Tazarotene. The re-differentiation events such as hair follicle growth are considered later morphogenetic 
events in the regenerative healing process34. Collagen is a major extracellular matrix component of skin 
and essential for the mechanical properties of the wounded region. We assessed the collagen fiber 
networks using staining with picrosirius red (a dye for collagen fiber maturity35). The new and mature 
collagen levels were increased in the regenerated area in the Tazarotene-treated group compared to the 
control group. Collagen fiber morphology and organization was close to that observed in the normal skin 
in the Tazarotene treated group (Fig. 6c). Proliferating cells were more abundant in regenerating area of 
the Tazarotene-treated group. The majority of the proliferating cells were epithelial (K14 positive) cells). 
Fewer proliferating cells were detected in the vessels or myofibroblasts (α-smooth muscle cell positive 
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cells) (Fig. 6d). Blood vessel densities in the regenerated ear margin of Tazarotene-treated mice were 
4.5-folds greater than that seen in Vehicle-treated mice (Fig. 6e). Confocal microscopy of ear whole 
mount revealed an augmented neovessel growth in the regenerated tissue of the Tazarotene-treated 
group at 14 days after injury. Notable, a significant increase of sprouting vessels towards the wound 
edge is detected as early as 4 days after injury (Fig 6f,g). The ear punch model provides cartilage as the 
wound bed. To further explore the therapeutic potential of Tazarotene in a model that does not involve 
cartilage, we have used a dermal excisional wound model. In agreement with our previous findings in 
the ear punch wound model, we found that animals treated with Tazarotene showed an acceleration of 
wound healing (Fig 7a). Histological analysis revealed that Tazarotene increased wound 
epithelialization (Fig 7b) and enhanced new microvessel growth (Fig 7c) in the wound bed compared to 
the control group. Together, these data show that Tazarotene induces wound tissue repair associated 
with increased neovascularization of the wound bed. 
 
Discussion 
In the present study, we used high content imaging techniques and a combination of two phenotypic 
angiogenesis assays to screen a small molecule library with well-defined targets.  This resulted in the 
identification of Tazarotene, a third generation retinoid agonist, as a pro-angiogenic small molecule. We 
showed that Tazarotene promotes blood vessel growth and functional neovascularization in several in 
vitro and in vivo systems that model angiogenesis.  
At a cellular level, we show that Tazarotene increases the generation of endothelial cell filopodial 
protrusions and tubule remodeling, resulting in a highly branched vascular network. The vascular 
network can be grown through elongation or branching of adjacent endothelial cells. When endothelial 
cells are seeded onto fibroblasts, they initially form clusters, which remodel later and sprout to form a 
vascular-like network36. Notably, Tazarotene predominantly accelerates this process of remodeling, by 
enhancing the differentiation of endothelial cells towards an elongated phenotype with increased 
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filopodia formation. Confirming this, Tazarotene enhances VEGFR3 transcription in endothelial cells. 
Importantly, VEGFR3 is increased in sprouting endothelial cells during the growth of new vessels17, and 
blockade of VEGFR3 signaling results in decreased sprouting, vascular density, vessel branching and 
endothelial cell proliferation37. By following tubule formation in co-cultures by time-lapse microscopy, 
it appears that Tazarotene enhances tubule remodeling rather than cell migration.  
Retinoids act via RARs and RXRs, nuclear transcription factors, which form homo and heterodimers 
that bind the enhancers of retinoid-responsive genes38. Using a pharmacological approach, we showed 
that the angiogenic phenotype induced by Tazarotene is dependent on the specific activation of RARs 
but not RXRs. The resemblance of the RARβ and RARγ dependent pro-angiogenic phenotypes in vitro 
is consistent with the binding of the active form of Tazarotene to all three RARs with increased 
selectivity for RARβ and RARγ, The induction of RARRES1 – a gene that is up regulated by RAR but 
not RXR specific synthetic retinoids24 – by Tazarotene in both endothelial cells and fibroblasts also 
supports the idea that RARs are instrumental in driving the Tazarotene-generated angiogenic phenotype. 
This is a novel supporting evidence that Retinoic acid can have angiogenesis-promoting activity 39. 
We showed that blockade of retinoic acid degradation, which leads to increase the intracellular level of 
retinoic acid, induces the sprouting angiogenic behavior of endothelial cells similar to Tazarotene. The 
intracellular level of retinoic acid is maintained by the balance between its synthesis and degradation 
into inactive products, and is regulated by an enzymatic network in which retinol dehydrogenases 
(RDH) and retinaldehyde dehydrogenases (RALDHs) synthesize, while cytochrome the P450 CYP26 
degrades retinoic acid40. This generates gradients of retinoic acid signaling activity that are distributed in 
a dynamic spatiotemporal manner to create important control mechanisms during organ 
development41,42. We speculate that such gradients may similarly program the sprouting and remodeling 
process during new vessel formation. The regulation of intracellular retinoic acid availability could thus 
be an important factor in controlling the different cellular events of angiogenesis. 
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In our study, an important observation is that the pro-angiogenic effect of Tazarotene is magnified when 
endothelial cells are co-cultured with fibroblasts, suggesting a role for paracrine secretions from 
fibroblasts in mediating this effect. We observed around 60% enhancement of tube formation when 
Tazarotene was added to endothelial cell/fibroblast co-culture. This is in contrast to around 18% 
enhancement of tube formation when Tazarotene was applied to endothelial cell culture. Consistent with 
this, we demonstrate that Tazarotene induces the secretion of the pro-angiogenic factors VEGFA, HGF, 
PGF43 and PLAU from fibroblasts. Moreover, Tazarotene decreases the secretion of PTX3, an inhibitor 
of angiogenesis 44. 
Our results indicate that in endothelial cell/fibroblast co-culture, Tazarotene enhances human fibroblast 
DNA synthesis. However Ogawa et al 45 reported a reduction in fibroblast DNA synthesis with 
Tazarotene when cultured in isolation.  We speculate that this difference may be due to the experimental 
conditions, the most important being that we used a co-culture with endothelial cells. 
The pro-angiogenic properties of Tazarotene, identified in our cell-based studies, were confirmed in 
relevant in vivo models – Matrigel implant and wound healing. In both models, angiogenesis is preceded 
by fibroblast growth and invasion. In the Matrigel plug model, we show that Tazarotene enhanced the 
formation of an anatomically mature neovessel network that was physiologically functional and able to 
receive blood flow. Moreover, we found that Tazarotene induced sprouting angiogenesis and capillary 
growth from an early stage of the healing process. Capillary growth into the wound allows delivery of 
nutrients, cells, and cytokines that mediate the healing response, and is necessary for metabolite 
removal. Insufficient angiogenesis thus impairs wound healing46. In our study, the induction of 
angiogenesis by Tazarotene was accompanied with histological signs of rapid repair in ear punch 
wounds as evidenced by increased regenerating tissue, establishment of organized mature collagen fiber 
network, increased proliferative activity in wound edges and hair follicle neogenesis. While retinoic acid 
can induce regeneration in a number of different organ systems in vertebrate such as the urodele 
amphibian limb 47, our data show that Tazarotene enhances both functional neovascularization and skin 
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tissue repair in adult mice, which are both essential components of the efficient repair process following 
injury.  
In summary, we demonstrate that Tazarotene promotes neovascularization and tissue repair through its 
action on retinoic acid signaling. At least in part, this is driven by a Tazarotene-induced pro-angiogenic 
paracrine signaling from fibroblasts. Tazarotene is a small molecule with a defined mechanism of action, 
and is approved for topical use by the FDA15. Oral Tazarotene does not appear to be associated with 
adverse events that are typical of oral retinoids, including hypertriglyceridemia and 
hypercholesterolemia48. Thus, re-purposing of Tazarotene could be explored for treatment of 
pathological conditions where circulatory insufficiency is a significant factor for instance in delayed 
wound healing 49.  
 
Materials and Methods  
Chemical compounds 
The LOPAC1280 library (Sigma) is a collection of 1280 pharmacologically active compounds from 56 
pharmacological classes with well-characterized properties. Compounds were dissolved in DMSO and 
transferred to 384-well plates and stored at -20°C. Upon hit identification, all selected enhancer 
compounds including Tazarotene were purchased as powders from Sigma. All compounds were 
dissolved and aliquoted in DMSO at 10mM. RARα selective agonist (BMS753), selective RARβ agonist 
(CD2314), selective RARγ agonist (BMS961), RXR agonist (SR 11237), pan-RAR inverse agonist 
(BMS493), pan RXR antagonist (UVI30003) and Liarozole hydrochloride were purchased from 
TOCRIS. All-trans-Retinoic Acid and 9-cis-Retinoic Acid were purchased from Sigma. 
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Development and miniaturization of endothelial tube formation assay for high throughput 
screenings 
Primary Human Umbilical Endothelial cells “HUVEC” were purchased from Lonza. Cells were 
maintained in endothelial cell Medium (EGM-2™, Lonza). Low passage cells (<5) were used for all 
experiments. The in vitro tube formation assay was performed as previously described for a 96-well 
microplate format13. In our study, we also adapted the assay for 384-well microplate format. Briefly, 
HUVEC were seeded at 15,000 cells per well for 96-well plate or 4,500 cells per well for 384-well plate 
on top of Matrigel (ref.354248, BD Bioscience) after adding compounds and incubated at 37°C, %5 CO2 
for eight hours. HUVEC formed capillary-like vascular structures "tubes" in the presence of the 
Matrigel. The tubes were fixed and stained with Alexa568-conjugated phalloidin (Invitrogen), HCS 
CellMask™ Green (Invitrogen) and DAPI (Invitrogen). Assays were performed in black-walled, clear-
bottom, 96-well and 384-well microplates (Perkin Elmer) suitable for automated fluorescent imaging. 
Images were acquired using a high-content imaging system (Operetta, Perkin Elmer). The raw (.tiff) 
images were then segmented and analyzed to extract the morphological features of vascular-like network 
using fully-automated Metamorph image analysis software (Molecular Devices). The Z’ factor was used 
to measure the robustness of the cell-based assay. It is defined by the following equation: 
 
 
 
Assays with Z>0.3 are considered highly suitable for conducting a high-throughput screening of assays 
with complex cellular systems such as capillary-like network formation50. We found that the most robust 
morphological parameter is total tube length (Z’ factor=0.33). For the actual screen, several other 
parameters depicting the network morphometric were also measured including branching points, average 
tube thickness, total tube area, total node area, tube length per set and segment number. 
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High content screening for regulators of angiogenesis  
Cooled Matrigel (16µl) was dispensed into black 384-well plates (F-bottomed, Cell carrier, Perkin 
Elmer) using liquid handling robotics (JANUS, Perkin Elmer) and incubated for one hour at 37°C. Next, 
library compounds (in 16µl media) were added to a final concentration of 10µM for further 30 min at 
room temperature. Suramin (inhibitor of angiogenesis)44 was added as positive control and 0.5% DMSO 
(Vehicle) was added as negative control. HUVEC (pooled donor, C2519A, Lonza, passage 4) were 
grown in EGM™-2 Media (Lonza). Cells were split using Accutase® (Sigma). Cells were then seeded in 
the prepared plates with compounds and Matrigel at density of 4,500 cells per well in 16µfgl with cell 
dispenser (FlexDrop PLUS) and liquid handling robotics (JANUS). Microplates were incubated for eight 
hours at 37°C, %5 CO2 until endothelial cells form capillary-like vascular structures "tubes". The screen 
was performed in duplicate. 
Endothelial tubes were fixed with paraformaldehyde 4% overnight at 4°C. After washing with PBS, 
cells were permeabilised with 0.1% Triton X-100 in PBS for 10 min. Cells were stained with alexa 
fluor-568 phalliodin (Invitrogen), 1:200 and HCS CellMask™ Green (Invitrogen), 1:5000 for 45 min at 
room temperature. Wells were washed three times with 0.05% TWEEN-20 in PBS.  Next, the plates 
were imaged with a 2x objective using a high-content microcopy system (Operetta, Perkin Elmer). A 
single field which covers the whole well was acquired at two wavelengths to image cell body (CellMask 
green) staining and actin phalloidin staining at exposure times of 50 and 400 milliseconds, respectively. 
The actin-phalloidin images (16-bit depth) were cropped using imageJ (NIH) to extract the region-of-
interest from the row images and to remove the out-of-focus objects in the border area of the well. Each 
resulting well image had a dimension of 400x400 pixels, which covers 45% of the total area of the well. 
Next, the processed images were segmented and analyzed to extract the morphological features of the 
vascular-like network using fully-automated Metamorph image analysis software (Molecular Devices). 
A pixel intensity threshold was set to distinguish actin-labeled endothelial tubes from local background 
along with a minimum and maximum tube width and applied for analysis of all images. 
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The total tube length and branching points reading values were normalized using the B-score method in 
the WebCellHTS2 package51. The hit selection threshold was set at +2.6 for enhancers and at -4.0 for 
inhibitors. R2 correlation between replicates was =0.7. The Z’ factor was used to assess the quality 
control of the screen plates, and was >0.3 in all plates (Supplementary Fig. 2a). The screen data and 
plate QC assessment were visualized and analyzed using Excel (Microsoft), Spotfire (TIBCO, Perkin 
Elmer) and Prism (GraphPad) software.   
 
Co-culture angiogenesis assay 
Adult human dermal fibroblasts (HDF, Lonza) were seeded at density 15,000 cells per well. Next day, 
HUVEC were plated at density 4,000 cells per well on the confluent fibroblast monolayer in 96-well 
plate as described previously52. The interaction of these two cell types gives rise to three-dimensional 
tubules over a period of 5-7 days. The drug is added one hour after plating of HUVEC to avoid potential 
secondary effect of the drug on cell adhesion. The co-cultures were fed with a full-growth factor 
supplemented medium consisting of a 1:1 mixture of medium-106 (Invitrogen): EGM-2 medium. 
Endothelial formed tubes were assessed by immunofluorescence using a mouse anti-human CD31 
monoclonal antibody (ref. BBA7, R&D systems) at 1:100 dilution and goat alexa 568-conjugated anti-
mouse IgG secondary antibody (Invitrogen) at 1:400 dilution. Nuclei were visualized by DAPI staining. 
The endothelial tubes were imaged automatically at 10x magnification using the high-content imaging 
system (Operetta). Typically, nine identically positioned fields were acquired from each well in each 
experiment. Quantification of the angiogenic parameters of formed endothelial network was performed 
automatically using Metamorph software.  
 
Heat map clustering and analysis for phenotypic profiling of compounds 
Prior to hierarchical clustering, data were scaled by performing Z score normalization for each 
angiogenic parameter. Z score–transformed values were then clustered using an unsupervised 
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agglomerative clustering method with an average linkage and a Euclidian distance measurement53. 
Hierarchical clustering of the compound phenotype profiles was carried out using TIBCO Spotfire 
software and data were visualized using the dendrogram for compounds with heat map for angiogenic 
parameter values.  
 
Cell proliferation assay  
Cell proliferation was assessed using Click-iT® EdU Alexa Fluor® 488 HCS kit (ref. C10350, 
Invitrogen) according to the manufacturer’s protocol. Briefly, HUVEC were seeded alone or on HDF 
monolayer in 96-well plates at 7.5×103 cells per well and treated with Tazarotene or Vehicle for 48 h. 
EdU labeling medium (10 µM final concentration) was added to the cell culture and incubated for 6 
hours before fixation. Next, the cultured cells were fixed with 4% paraformaldehyde for 10 min and 
treated with 0.1% Triton X-100 for 15 min at room temperature. After washing with PBS, the samples 
were stained with Click-iT® reaction cocktail working solution at room temperature for 30 min. The 
cells were stained with DAPI at room temperature for 20 min. In co-culture experiments, endothelial 
cells were stained with mouse anti-human CD31 antibody (R&D systems) and subsequent incubation 
with alexa568-conjugated goat anti-mouse IgG secondary antibody (Invitrogen). The plates were imaged 
and quantified using high-content fluorescent microscopy (Operetta). The total cell number and 
percentage of EdU-positive cells was calculated from 9 fields per well using a 10x objective (Harmony 
software, Perkin Elmer). The image analysis software (Harmony) has the required algorithms to be able 
to distinguish the nuclei in stained endothelial tubes from the ones of fibroblasts. 
 
Time-lapse live cell imaging and cell motility assessment  
HUVEC stably expressing eGFP were obtained by transduction of eGFP-puro-lentiviral vector 
(GeneCopoeia). HUVEC expressing eGFP were seeded in 96-well plate as single cells or were co-
cultured with fibroblasts in presence of Tazarotene (7 µM) or Vehicle. Time-lapse live imaging was 
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performed in a humidified, heated and CO2-controlled and integrated chamber within the high-content 
imaging system (Operetta). For cell motility assessments, images were captured with 10x objective at 15 
min intervals for a total period of 24 hours. Individual cells were identified and tracked automatically 
within the field image using Harmony image analysis software. For observing tubulogenesis, images 
were captured with 10x objective at 15 min interval for a total period of 48 hours.   
 
Proteome profiler array for angiogenic factors 
The Proteome Profiler Human angiogenesis-related cytokines Array Kit (R&D Systems, Catalog # 
ARY007) was used to analyze secretory changes in the conditioned medium of fibroblasts following 
Tazarotene or Vehicle treatments for 48 hours essentially according to the manufacturer's instructions, 
but using IRDye® 800CW streptavidin. Visualization and quantitation of the detected spots were 
performed using the LI-COR Odyssey scanner and Odyssey 3.0 analytical software (LI-COR 
Biosciences). Pixel density values in dot blots were corrected by normalizing to the highest average 
control and subtracting the average pixel density values of negative controls. The map array of cytokines 
is illustrated in (supplementary Fig. 5). 
 
Quantitative RT-PCR 
Total RNA was isolated from cultured cells using the Qiagen RNeasy Micro Kit and from the mouse 
liver using the Qiagen RNeasy Mini Kit according to the manufacturer’s protocol. cDNA was prepared 
with QuantiTect Reverse Transcription Kit (Qiagen). SYBR green qPCR was carried out with the 
following QuantiTect Primer Assay assays: Human FLT4, Hs_FLT4_1_SG (QT00063637), Human 
KDR, Hs_KDR_1_SG (QT00069818), Human RARRES1, Hs_RARRES1_2_SG, (QT01666469)   
Human PGF, Hs_PGF_1_SG (QT00030688), Human PTX3, Hs_PTX3_1_SG (QT00093261) and 
mouse RARRES1, Hs_RARRES1_2_SG, (QT01666469) . The data were normalized to the 
endogenous controls HPRT1, Hs_HPRT1_1_SG, (QT00059066) for cells and 18S ribosomal RNA, 
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Mm_Rn18s_3_SG, (QT02448075) for murine samples. Fold changes were calculated using comparative 
ddCT (threshold cycle) method (BioRad). 
 
ELISA 
We used commercially available enzyme-linked immunosorbent assay (ELISA) kits (DuoSet, R&D 
systems) to measure thuman Placental Growth factor (PGF) and Pentatraxin 3 (PTX3) levels in cell 
culture supernatants. 
 
In vivo Matrigel implant angiogenesis assay 
Experiments involving mice were covered by project and personal licenses issued by the UK Home 
Office and they were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (the Institute of Laboratory Animal Resources, 1996). Eight-week old female CD1 mice 
(Harlan Laboratories) were injected subcutaneously into both abdominal flanks with 400µl growth 
factor-reduced Matrigel (BD Bioscience) supplemented with FGF2 (250ng/ml, R&D systems), under 
anesthesia induced by isoflurane inhalation. Mice were daily injected intra-peritoneally (i.p.) with either 
Tazarotene (10mg/kg) or 2.5% DMSO in PBS (Vehicle) starting from the day of Matrigel implantation 
for 6 days. Twelve days later, the mice were killed and Matrigel implants were removed, photographed 
and fixed in 4% paraformaldehyde at 4°C overnight. Implant paraffin sections of 7µm thickness were 
incubated with the rat anti-mouse CD31 antibody (1:100, BD Biosciences, 550274) overnight at 4ºC. 
Sections were then incubated with alexa488 conjugated goat anti-rat IgG secondary antibody 
(Invitrogen) and cy3-conjugated anti–α-smooth muscle actin antibody (Sigma). Nuclei were 
counterstained with DAPI. Mounted sections were imaged with 20x objective by Operetta imaging 
system (Perkin Elmer). Microvessel density was quantified in 30-40 fields covering the whole cross-
section of the Matrigel plug at each of three 1-mm spaced sectioning planes of implants. CD31 positive 
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neovessel area covered with α-smooth muscle actin positive cells inside implants and total implant area 
were quantified using Image J software (NIH). 
To visualize microvessel perfusion, terminally anesthetized mice were injected intracardially with 
3mg/kg of biotinylated GS-IsolectinB4 (invitrogen). After 5 min, mice were euthanized and perfused 
with 4% neutral buffered paraformaldyhede under physiological pressure. Implants were dissected and 
stored in PFA 4% overnight. Following an incubation in 30% (w/v) sucrose solution, the plugs were 
embedded in OCT compound and were snap frozen. Implants were cut into thick sections (200µm) and 
labeled for injected lectin by incubating with alexa647-conjugated streptavidin. Co-staining is applied to 
visualize the total vessels by incubating with anti-CD31 antibody as described above. Fluorescence 
images of stained slices were taken with a confocal laser-scanning microscope (Zeiss 510 Metahead). 
Around 50 z-stacks of raw images (xy) were required for 3D reconstruction. 
 
MicroCT angiogram 
Mice were euthanized, and the thoracic cavity was opened. The right atrium was cut, and the heart (left 
ventricular) flushed with PBS containing heparin (1000 IU/L) for 5 min. 4% neutral buffered 
paraformaldyhede was perfused under physiological pressure for an additional 5 min. A contrast agent, 
radiopaque silicone rubber compound (Microfil, MV-112, Flow Tech Inc.), was injected into the heart 
for 5 min as described previously54. Obvious perfusion in the eyes and tail served as a reliable marker 
for systemic perfusion of the blood circulation. The mice were left at room temperature for 30 min to 
allow polymerization of the agent. Matrigel implants including the overlying skin were generously 
dissected, placed into 4% neutral buffered paraformaldehyde and maintained at 4°C until scanning. The 
skin over the implants was served for the sample orientation. The samples were embedded in agarose gel 
and imaged using a SkyScan 1172 microCT scanner (Bruker). The 3D micro-CT scans of each Matrigel 
implant were visualized using Imaris image analysis software (Bitplane). The raw images were 3D 
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reconstructed, segmented and quantified using Amira 5.5.3 image analysis software (FEI Visualization 
Sciences Group). 
 
Ear punch wound healing model 
Eight-week old female CD1 mice (Harlan Laboratories) were used for an ear wounding procedure as 
described previously55. All procedures were carried out according to UK Home Office regulations and 
under appropriate licences. Briefly, mice were wounded with a 2-mm full-thickness hole punched 
through the lateral third of each ear using a sterile metal biopsy punch (Harvard Apparatus). The wound 
was disinfected with ethanol swabs to prevent infection. Mice were daily injected intra-peritoneally with 
either Tazarotene (10mg/kg body weight) or DMSO 2.6% in PBS (Vehicle) starting from the day of 
wounding for 6 days. Wounds were photographed with a digital camera immediately after wounding and 
at day 12. Mice were killed after 12 days or 14 days of wounding, ears were harvested and fixed in 4% 
neutral buffered paraformaldehyde. A coverslip was laid on top of the ear tissue for flattening. Ear 
wound images were captured and processed by using stereomicroscope linked to digital camera. Ear 
hole area (in mm2) was quantified by using ImageJ image analysis software. Tissue from wounded ears 
was fixed with PFA 4% at 4°C overnight, embedded in paraffin and 7-µm thick sections cut. Before 
histological staining, slides were dewaxed and rehydrated. Slides were stained with Hematoxylin and 
Eosin (H&E) or a Picro-Sirius Red stain kit (Sigma). The slides were washed, rehydrated, cleared and 
mounted. Staining was visualized using Nikon microscope in bright field for Hematoxylin and Eosin 
(H&E) and under polarized light for Picro-Sirius Red. The Picro-Sirius Red signal was measured in the 
marginal area of wounds and quantified using Image J software. For labeling of proliferating cells, mice 
were injected i.p. with 3 mg/kg of EdU (Invitrogen) 24 hours before euthanasia. Ear wound paraffin 
sections were stained for EdU using Click-iT chemistry following the manufacturer’s instructions 
(Invitrogen). For vascular phenotypic analysis, whole mount preparations of dissected ear skins or 
paraffin cross-sections were double immunostained. Briefly, after blocking with 5% goat serum in PBST 
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(0.3% TWEEN-20 in PBS), samples were incubated with anti-mouse CD31 antibody (BD Biosciences). 
Samples were incubated for with alexa488-conjugated goat anti-rat IgG secondary antibody (Invitrogen) 
and Cy3-conjugated anti--SM actin antibody (Sigma). Nuclei were counterstained with DAPI 
(Invitrogen). CD31-positive blood vessel area was quantified in the marginal area of wounds using 
Image J software. Fluorescent images from flat-mounted ear skins were visualized using a Leica SP8 
SMD X Confocal Microscope. Around 60 z-stacks of raw images (xy) were typically acquired for 3D 
reconstruction. 
 
Laser speckle contrast imaging of blood flow 
Blood flow in the ear wounds was monitored using a Speckle Contrast Imager - FLPI-2 (Moor 
Instruments, UK) as described previously56. The FLPI measurements were made in a warm (24 °C) and 
quiet environment. The CCD camera was positioned 30 cm above the ear internal surface. The contrast 
images were processed to produce a color-coded live flux image (red denoted high perfusion, blue 
signified low perfusion) using the moorFLPI-2 measurement module (Moor Instruments). Measurements 
were made postoperatively in the periphery area of wounds at 6 and 12 days using the moorFLPI-2 
review module (Moor Instruments). 
 
Excisional dorsal wound healing model 
Eleven-week old female CD1 mice (Harlan Laboratories) were used for cutaneous wounding procedure 
as described previously57. All procedures were carried out according to UK Home Office regulations and 
under appropriate license. Mice were anesthetized, and their dorsal skin was shaved and wiped with 70% 
ethanol. Full-thickness excisional wounds were made by picking up a fold of skin and using a sterile, 
disposable 5-mm biopsy punch, resulting in generation of one wound on each side of the midline. Mice 
were daily injected intra-peritoneally with either Tazarotene (10mg/kg body weight) or DMSO 2.6% in 
PBS (Vehicle) starting from the day of wounding for 6 days. The areas of open wounds were measured 0 
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and 8 days after wounding. Mice were killed after 8 days of wounding, wounds were harvested with a 5-
mm rim of unwounded skin tissue and fixed in 4% neutral buffered paraformaldehyde. For 
immunostaining, paraffin sections were incubated with a rat monoclonal specific for endothelial cells 
(CD31, BD Bioscience), Cy3-conjugated anti-α-SM actin antibody (Sigma) for smooth muscle cells and 
myofibroblasts and K14 for keratinocytes (GeneTex). CD31-positive blood vessel area was quantified in 
the wound edges using Image J software. 
 
Statistics 
All statistical analysis was carried out using Prism GraphPad. Two treatment groups were compared by 
unpaired-t-test. Multiple group comparisons were analyzed by one-way or two-way ANOVA with post 
hoc Bonferroni’s test. A p value of less than 0.05 was considered to be statistically significant. Several 
independent experiments were performed to guarantee reproducibility of findings.  
 
Acknowledgments. A.A is supported by the intermediate fellowship awarded by the Oxford British 
Heart Foundation (BHF) Centre of Research Excellence (RE/08/004/23915). J.E.S is supported by a 
BHF Senior Basic Science Research Fellowship (FS/11/50/29038). A.C is supported by a BHF 
Intermediate Basic Science Research Fellowship (FS/11/52/29018). This study was funded by the 
Oxford BHF Centre of Research Excellence (RE/08/004 and RE/13/1/30181), BHF program grant 
(RG/11/1/28684), and BHF Chair Award (CH/09/003). The authors acknowledge Wellcome Trust Core 
Award (090532/Z/09/Z). 
 
Ac
c
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
References 
 
1. Ferrara, N. & Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 438, 967-74 (2005). 
2. Adams, R.H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat 
Rev Mol Cell Biol 8, 464-78 (2007). 
3. Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 
146, 873-87 (2011). 
4. Henry, T.D. et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular 
Angiogenesis. Circulation 107, 1359-65 (2003). 
5. Barrientos, S., Brem, H., Stojadinovic, O. & Tomic-Canic, M. Clinical application of growth 
factors and cytokines in wound healing. Wound Repair Regen 22, 569-78 (2014). 
6. Loges, S., Roncal, C. & Carmeliet, P. Development of targeted angiogenic medicine. J Thromb 
Haemost 7, 21-33 (2009). 
7. Simons, M. & Ware, J.A. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug 
Discov 2, 863-71 (2003). 
8. Al Haj Zen, A. et al. Inhibition of delta-like-4-mediated signaling impairs reparative 
angiogenesis after ischemia. Circ Res 107, 283-93 (2010). 
9. Lenard, A. et al. In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular 
anastomosis. Dev Cell 25, 492-506 (2013). 
10. Zanella, F., Lorens, J.B. & Link, W. High content screening: seeing is believing. Trends 
Biotechnol 28, 237-45 (2010). 
11. Arnaoutova, I., George, J., Kleinman, H.K. & Benton, G. The endothelial cell tube formation 
assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12, 267-74 
(2009). 
A
ce
pte
d m
an
us
cr
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
12. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev 
Cancer 3, 422-33 (2003). 
13. Arnaoutova, I. & Kleinman, H.K. In vitro angiogenesis: endothelial cell tube formation on gelled 
basement membrane extract. Nat Protoc 5, 628-35 (2010). 
14. Elkins, J.M. et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nat 
Biotechnol 34, 95-103 (2016). 
15. Weindl, G., Roeder, A., Schafer-Korting, M., Schaller, M. & Korting, H.C. Receptor-selective 
retinoids for psoriasis: focus on tazarotene. Am J Clin Dermatol 7, 85-97 (2006). 
16. Sakamoto, K. et al. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is 
associated with the level of H3K4me2 in the RARalpha promoter region. Blood Cancer J 4, e205 
(2014). 
17. Siekmann, A.F. & Lawson, N.D. Notch signalling limits angiogenic cell behaviour in developing 
zebrafish arteries. Nature 445, 781-4 (2007). 
18. Benedito, R. et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-
VEGFR2 signalling. Nature 484, 110-4 (2012). 
19. Nagpal, S., Athanikar, J. & Chandraratna, R.A. Separation of transactivation and AP1 
antagonism functions of retinoic acid receptor alpha. J Biol Chem 270, 923-7 (1995). 
20. Zhao, X., Graves, C., Ames, S.J., Fisher, D.E. & Spanjaard, R.A. Mechanism of regulation and 
suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene 
carbohydrate sulfotransferase 10. Cancer Res 69, 5218-25 (2009). 
21. Chen, J.Y. et al. Two distinct actions of retinoid-receptor ligands. Nature 382, 819-22 (1996). 
22. Zirn, B. et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes 
associated with high risk and relapse in vivo. Oncogene 24, 5246-51 (2005). 
23. Van Wauwe, J. et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic 
effects in vivo. J Pharmacol Exp Ther 261, 773-9 (1992). 
Ac
ce
pte
d m
an
us
cr
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
24. Nagpal, S. et al. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive 
gene in skin. J Invest Dermatol 106, 269-74 (1996). 
25. Takami, Y., Yamamoto, I., Tsubouchi, H. & Gohda, E. Modulation of hepatocyte growth factor 
induction in human skin fibroblasts by retinoic acid. Biochim Biophys Acta 1743, 49-56 (2005). 
26. Chen, J.T., Liang, J.B., Chou, C.L., Shyu, R.C. & Lu, D.W. Retinoic acid induces VEGF gene 
expression in human retinal pigment epithelial cells (ARPE-19). J Ocul Pharmacol Ther 21, 413-
9 (2005). 
27. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth 
factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 
7, 575-83 (2001). 
28. Inforzato, A. et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer 
with two binding sites for FGF2. J Biol Chem 285, 17681-92 (2010). 
29. Brown, N.J., Smyth, E.A., Cross, S.S. & Reed, M.W. Angiogenesis induction and regression in 
human surgical wounds. Wound Repair Regen 10, 245-51 (2002). 
30. Rajnoch, C. et al. Regeneration of the ear after wounding in different mouse strains is dependent 
on the severity of wound trauma. Dev Dyn 226, 388-97 (2003). 
31. Metcalfe, A.D., Willis, H., Beare, A. & Ferguson, M.W. Characterizing regeneration in the 
vertebrate ear. J Anat 209, 439-46 (2006). 
32. Buckley, G., Metcalfe, A.D. & Ferguson, M.W. Peripheral nerve regeneration in the MRL/MpJ 
ear wound model. J Anat 218, 163-72 (2011). 
33. Zhang, Y. et al. Drug-induced regeneration in adult mice. Sci Transl Med 7, 290ra92 (2015). 
34. Clark, L.D., Clark, R.K. & Heber-Katz, E. A new murine model for mammalian wound repair 
and regeneration. Clin Immunol Immunopathol 88, 35-45 (1998). 
35. Pickering, J.G. & Boughner, D.R. Quantitative assessment of the age of fibrotic lesions using 
polarized light microscopy and digital image analysis. Am J Pathol 138, 1225-31 (1991). 
cc
ep
t d
 m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
36. Mavria, G. et al. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival 
and sprouting during angiogenesis. Cancer Cell 9, 33-44 (2006). 
37. Tammela, T. et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network 
formation. Nature 454, 656-60 (2008). 
38. di Masi, A. et al. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol 
Aspects Med 41, 1-115 (2015). 
39. Gaetano, C. et al. Retinoids induce fibroblast growth factor-2 production in endothelial cells via 
retinoic acid receptor alpha activation and stimulate angiogenesis in vitro and in vivo. Circ Res 
88, E38-47 (2001). 
40. Cunningham, T.J. & Duester, G. Mechanisms of retinoic acid signalling and its roles in organ 
and limb development. Nat Rev Mol Cell Biol 16, 110-23 (2015). 
41. Shimozono, S., Iimura, T., Kitaguchi, T., Higashijima, S. & Miyawaki, A. Visualization of an 
endogenous retinoic acid gradient across embryonic development. Nature 496, 363-6 (2013). 
42. Duester, G. Retinoic acid synthesis and signaling during early organogenesis. Cell 134, 921-31 
(2008). 
43. Autiero, M., Luttun, A., Tjwa, M. & Carmeliet, P. Placental growth factor and its receptor, 
vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue 
revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1, 
1356-70 (2003). 
44. Rusnati, M. et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 
inhibits angiogenesis. Blood 104, 92-9 (2004). 
45. Ogawa, A. et al. Effect of tazarotene, an acetylenic retinoid, on human dermal fibroblast. Jpn J 
Pharmacol 76, 317-9 (1998). 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
46. Rossiter, H. et al. Loss of vascular endothelial growth factor a activity in murine epidermal 
keratinocytes delays wound healing and inhibits tumor formation. Cancer Res 64, 3508-16 
(2004). 
47. Maden, M. & Hind, M. Retinoic acid, a regeneration-inducing molecule. Dev Dyn 226, 237-44 
(2003). 
48. Jones, P.H. et al. A phase 1 study of tazarotene in adults with advanced cancer. Br J Cancer 89, 
808-15 (2003). 
49. Falanga, V. Wound healing and its impairment in the diabetic foot. Lancet 366, 1736-43 (2005). 
50. Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73 
(1999). 
51. Pelz, O., Gilsdorf, M. & Boutros, M. web cellHTS2: a web-application for the analysis of high-
throughput screening data. BMC Bioinformatics 11, 185 (2010). 
52. Abraham, S. et al. A Rac/Cdc42 exchange factor complex promotes formation of lateral 
filopodia and blood vessel lumen morphogenesis. Nat Commun 6, 7286 (2015). 
53. Freeley, M. et al. A high-content analysis toolbox permits dissection of diverse signaling 
pathways for T lymphocyte polarization. J Biomol Screen 15, 541-55 (2010). 
54. Lee, S., Barbe, M.F., Scalia, R. & Goldfinger, L.E. Three-dimensional reconstruction of 
neovasculature in solid tumors and basement membrane matrix using ex vivo X-ray 
microcomputed tomography. Microcirculation 21, 159-70 (2014). 
55. Buckley, G., Wong, J., Metcalfe, A.D. & Ferguson, M.W. Denervation affects regenerative 
responses in MRL/MpJ and repair in C57BL/6 ear wounds. J Anat 220, 3-12 (2012). 
56. Rege, A., Thakor, N.V., Rhie, K. & Pathak, A.P. In vivo laser speckle imaging reveals 
microvascular remodeling and hemodynamic changes during wound healing angiogenesis. 
Angiogenesis 15, 87-98 (2012). 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
57. Canesso, M.C. et al. Skin wound healing is accelerated and scarless in the absence of commensal 
microbiota. J Immunol 193, 5171-80 (2014). 
58. Perlman, Z.E. et al. Multidimensional drug profiling by automated microscopy. Science 306, 
1194-8 (2004). 
 
 
 
 
 
 
 
 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2016 The American Society of Gene & Cell Therapy. All rights reserved 
Figure Legends 
 
Figure 1 Phenotypic screen for angiogenic activity of LOPAC1280 small molecule library. a) Left: 
Screening workflow. Primary Human Umbilical Vein Endothelial Cells (HUVEC) were seeded onto 
Matrigel coated 384-well plates and incubated with LOPAC1280 compounds at a concentration of 10 µM. 
Right: Plate design. The position of negative controls (Vehicle (DMSO) alone, blue), positive controls 
(Suramin, 10µM, red) and LOPAC1280 small molecules (green) is indicated. b) Image analysis 
workflow: Top: Endothelial tubes were stained for F-actin using phalloidin and CellMask Green and 
then imaged using an Operetta high content microcopy system. The region-of-interest (ROI, middle 
panel) is created on 16-bit red channel images and is followed by automated image segmentation 
(bottom panel) to identify tubes (white mask), nodes (green), and branching points (red dots) using 
Metamorph image analysis software (Molecular Devices). Scale bar 1 mm. c) Left: Scatter-plot 
distribution showing the results of high content screening. The total tube length was normalized using 
the B-score method in WebCellHTS2. Inhibitors and enhancers (B-Score ≤-4 and ≥+2.6 respectively) 
are indicated below and above the orange lines. Negative controls (are shown in blue positive controls in 
red and LOPAC1280 library molecules in green. Right, Representative microscopic images from negative 
(Vehicle alone) and positive (suramin) control wells, Scale bar 400 µm.  
 
Figure 2 Validation of active lead compounds. a) Selected enhancer hits were re-tested manually using 
the endothelial tube formation assay in 96-well format. The tubes were imaged and quantified as 
described in Figure 1. Left: Representative images of active lead compounds at 10µM. Scale bar 500µm.  
Right, the chemical structure, the molecular weight, the primary target of the compound and its effect on 
the total tube length (normalized to Vehicle %100), n=3 each concentration. Data are expressed as 
mean±s.e.m, one-way ANOVA followed by Bonferroni's post hoc test, **p<0.01; ***p<0.001 compared 
to Vehicle. b) The effect of active lead compounds was tested in an organotypic angiogenesis assay 
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where HUVECs are plated on to a confluent human dermal fibroblast (HDF) layer. The medium 
containing the compound (7µM) was refreshed at 3 and 5 days following plating of endothelial cells. 
Co-cultures were stained with an antibody against CD31 and imaged 7 days after endothelial cell 
plating. Nine fields were quantified for each well (n=6 wells per group). Error bars, mean±s.e.m, one-
way ANOVA followed by Bonferroni's post hoc test, *p<0.05; ***p<0.001 compared to Vehicle. Scale 
bar 1mm. c) Dose-response curve showing the effect of Tazarotene on total tube length using the 
organotypic angiogenesis assay. Data are shown as mean±s.e.m. The curve was fitted using Prism 
GraphPad, and EC50 calculated as 0.8µM. Scale bar 200 µm. d) High-power image of Vehicle and 
tazarotene treated endothelial tubes, demonstrating lateral filopodia protrusions (arrows). Scale bar 50 
µm e) Effect of Tazarotene (3 µM) on expression of FLT4 (VEGFR3) and KDR (VEGFR2) in cultured 
endothelial cells estimated using RT-qPCR. Error bars, mean±s.e.m., *P=0.02 compared to Vehicle, 
(n=3 replicates derived from 3 independent experiments, analysed using unpaired t-test). 
 
Figure 3 Tazarotene induces angiogenesis through RAR activation. HUVEC were seeded on to 
confluent human dermal fibroblast (HDF) cells. Medium containing the compound (3 µM) was 
refreshed 3 days following plating of endothelial cells. Co-cultures were stained with anti-CD31 and 
imaged 5 days after endothelial cell plating. Angiogenic phenotype parameters (total tube length, 
branching points, tube thickness, and total node area) of the formed network were measured using 
Metamorph image analysis software. Nine fields were quantified for each well as described in the 
methods. a) Effect of natural retinoic acids (all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid), 
RAR isoform agonists (RARα (BMS753), RARβ (CD2314) and RARγ(BMS961)) and RXR agonist (SR 
11237) on angiogenic phenotype, compared to the Tazarotene-induced phenotype (n=3 wells per 
condition). Error bars, mean±s.e.m, one-way ANOVA followed by Bonferroni's post hoc test, **p<0.01; 
***p<0.001 compared to Vehicle. Scale bar 200 µm. Right, Heatmap of z-score scaled data from the 
four angiogenic parameters, followed by hierarchical clustering of compounds to create the dendrogram 
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generated by Spotfire software58. Compounds clustering together, exhibit similar phenotypic profiles58. 
b) Effect of the pan-RXR antagonist (UVI 3003), pan-RAR antagonist (BMS5493) and Tazarotene on 
angiogenic phenotype (n=3 wells per conditions). Error bars, mean±s.e.m, one-way ANOVA followed 
by Bonferroni's post hoc test, ***p<0.001. Scale bar 200 µm. Right, compound phenotypic profiling 
using hierarchical cluster analysis as described above. c) Effect of Liarozole (3 µM), a retinoic acid 
metabolism inhibitor, on angiogenic phenotype, n=6 wells per conditions. Data are expressed as 
mean±s.e.m. Unpaired-t-test, **p<0.01; ***p<0.001 compared to Vehicle. Scale bar 200µm. d) 
RARRES1 mRNA abundance in Tazarotene-treated HUVEC and HDF assessed by quantitative RT-
PCR (n=3 replicates derived from 3 independent experiments). Unpaired-t-test, **p<0.01 compared to 
Vehicle. 
 
Figure 4 Tazarotene enhances the pro-angiogenic paracrine effects of fibroblasts.  a) Left, representative 
images showing the effect of Tazarotene (7 µM) on cell number and DNA synthesis in isolated 
HUVECs. HUVEC were cultured as single cells in presence of Tazarotene or Vehicle for 48 hours. EdU 
(10µM) was added 6 hours before fixation. Cells were stained for EdU (green) and DAPI (blue). Scale 
bar 200µm. b) Left, representative images showing the effect of Tazarotene (7 µM) on cell number and 
DNA synthesis in HUVEC/HDF co-culture at presence of Tazarotene or Vehicle for 48 hours. Cells 
were stained for EdU (green) and CD31 (red). Scale bar 200µm. Right panels of a) and b), quantitative 
data for total cell number and the proportion of EdU positive nuclei. Cell counts and EdU positive cells 
were normalised to the Vehicle control, which was set at 100%.  Data from 4 wells for each 
concentration, and nine fields per well were analysed, and are expressed as mean±s.e.m. One-way 
ANOVA followed by Bonferroni's post hoc test, *p<0.05; **p<0.01; ***p<0.001 compared to Vehicle. 
c) Effect of 5µM , representative images showing the effect of Tazarotene ted secreted proteins from 
HDF cells using Proteome Profiler ArrayTM. The inset shows the raw images from the array membrane 
for Vehicle (top) and Tazarotene (below), with letters corresponding to those on the bar-graph. 
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Fluorescence intensity of each dot was normalized to the Vehicle control and presented as fold change 
(y-axis) on the bar graph. d) Effect of 3 µM Tazarotene PGF and PTX3 mRNA expression estimated by 
quantitative RT-PCR. Error bars, mean±s.e.m. n=3. Unpaired-t-test, **p<0.01 compared to Vehicle. (e) 
Effect of Tazarotene on secreted PGF and PTX3 assayed by ELISA. n=3 per treatment condition, error 
bars, mean±s.e.m. One-way ANOVA followed by Bonferroni's post hoc test, *p<0.05; **p<0.01; 
***p<0.001 compared to Vehicle. 
 
Figure 5 Tazarotene promotes functional neovascularization in Matrigel implants. Mice were 
injected subcutaneously with Matrigel supplemented with FGF-2 (250 ng/ml). Tazarotene (10 mg/kg) or 
Vehicle (DMSO) was injected intra-peritoneally (i.p.) daily for 6 days. a) Representative photographs of 
implants from Vehicle control and Tazarotene treated mice. b) Effect of Tazarotene on neovessel 
formation. Top: Histological sections of Matrigel implants double immunostained for CD31 (endothelial 
marker, green) and α-smooth muscle actin (α-SM actin, smooth muscle cell marker, red). The dotted line 
shows the edge of Matrigel implant. Scale bar 120µm. Bottom: Mature neovessel area (y-axis) in the 
Matrigel plug was quantified by measuring CD31-positive neovessel invested by α- smooth muscle 
actin–positive cells stained areas in three sections (with a 1-mm interval between sections) for each 
implant and divided by total implant area, n=6 animals per treatment group, 2 implants per animal were 
studied. Data are presented as box plots, with maximum, minimum, and quartile range. Two-way 
ANOVA (****p<0.0001) followed by Bonferroni's multiple comparisons test, *p<0.05, ***p<0.001 
compared to Vehicle group. c) Effect of Tazarotene on microvessel perfusion using microCT 
angiography. Top, microCT angiogram of Matrigel implants. Mice were infused with Microfil 12 days 
after Matrigel implantation and the harvested implant analysed by 3D microCT imaging to visualize the 
microvasculature (orange). Middle: 3D-reconstruction of microCT images of Matrigel implants 
including the perfused microvessels: vessels inside Matrigel (green), vessels surrounding Matrigel (red) 
and the Matrigel implant (transparent grey). Bottom: The vessel volume inside the Matrigel was 
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quantified using Amira image analysis software. Data are expressed as % (vessel volume/Matrigel 
implant volume) by box plots, with maximum, minimum, and quartile range, n=6 mice, 2 implants per 
treatment group.  Unpaired-t-test,  *p<0.05 compared to Vehicle group. Scale bar 2mm. d) Effect of 
Tazarotene on microvessel perfusion using confocal microscopy. Representative Z-stack confocal 
images of thick sections of Matrigel implants (n=3 mice, 2 implants per treatment).  To visualize vessel 
perfusion, terminally anaesthetised mice were injected with biotinylated IsolectinB4 12 days after 
implantation, implants harvested and sections immunolabeled for CD31 (green, endothelial cells), α-SM 
actin (red, smooth muscle cells), DAPI (Blue, Nuclei), and for injected lectin by using streptavidin-
Alexa 647 (purple, perfused vessels). The dotted line shows the edge of Matrigel implant. Scale bar 
120µm. 
 
Figure 6 Tazarotene promotes ear punch wound healing and neovascularization after injury. a) 
Effect of Tazarotene on ear punch closure. Left: Representative images of ears from mice treated with 
Vehicle or Tazarotene.  Tazarotene (10 mg/kg, i.p.) was administered daily for 6 days following the ear-
punch. Wound size was measured after 12 days. Right: Quantification of the punch area (n=6 animals 
per group). Data are presented as box plots, with maximum, minimum, and quartile range, unpaired-t-
test, ***p<0.001 compared to Vehicle group. b) Left: Effect of Tazarotene on blood flow following ear-
punch injury. Representative images showing blood flow measured in the wound area using speckle 
contrast laser imaging at 6 and 12 days after injury (n=5 animals per group). The dotted circle denotes 
the region-of-interest.  Right: Mean flow (flux) in the region-of interest was quantified using moorFLPI-
2 software, and data expressed as mean ± s.e.m. Two-way ANOVA (**p<0.01) followed by 
Bonferroni's multiple comparisons test, *p<0.05 compared to Vehicle. c) Effect of Tazarotene on wound 
histology at 14 days after injury. Left: Hematoxylin and eosin stained cross-sections with the 2-mm area 
of the original hole indicated. Arrows indicate the initial wound site identified by the cartilage cut. 
Middle: Enlargement of the boxed section in the previous panel. Arrow-heads indicate new hair follicles 
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in the wound bed. Right: Picrosirius red stained cross-sections. Birefringence of picrosirius differentiates 
thick, mature collagen fibers (red/yellow) from thin, new collagen (green). Quantification of collagen 
density, data expressed as % (stained collagen area/regenerated area), n=6 animals per group. Unpaired-
t-test, *p<0.05 compared to Vehicle. Dotted line shows the initial cut position. Scale bar 90µm. d) Effect 
of Tazarotene on cell proliferation in the wound area. Left: Representative confocal images of ear wound 
at 6 days after injury stained with upper panel, CD31 (green), α-SM actin (red), DAPI (blue) and EdU 
(white); lower panel, stained with EdU (green), Keratin 14 “K14” (red) and DAPI (blue). The arrow 
indicates the initial wound site. Scale bar 90 µm. Right: EdU positive cells were quantified and 
normalized to the total cell number inside the regenerated area which is identified by the cartilage cut, 
n=4 animals per treatment condition. Data are expressed as mean±s.e.m. Unpaired-t-test, ***p<0.001 
compared to vehicle group. e) Effect of Tazarotene on wound neovascularization at 14 days after injury. 
Left: Cross sections of ear punches were stained with CD31 (green), α-SM actin (red) and DAPI 
(nuclei). Arrows indicate the initial wound site. Scale bar 90 µm.  Right: CD31-positive microvessel area 
was quantified as a percentage of the regenerated area, n=6 animals per group. Unpaired-t-test, 
***p<0.001 compared to Vehicle groupf, g) Effect of Tazarotene on new vessel formation in the 
regenerating zone. Z-stack confocal images of flat mounted ears at day 4 (f) and day 14 (g) after injury. 
The dotted line indicates the wound site, the arrows shows new hair follicles, and the asterisk indicates 
the ear hole. CD31 (green, endothelium) and -SM actin (red, smooth muscle cell and myofibroblasts).  
Insets in (g) show a global view of the wound at low magnification. Scale bar 90 µm. 
 
Figure 7. Tazarotene enhances excisional dorsal wound healing and wound bed vascularization. a) 
Effect of Tazarotene on wound closure. Left: Representative images of skin from mice treated with 
Vehicle or Tazarotene. Scale bar 5mm Right: Quantification of the wound closure (n=6 animals per 
group). Data are presented as box plots, with maximum, minimum, and quartile range, unpaired-t-test, 
*p<0.05 compared to Vehicle group. b) Effect of Tazarotene on wound epithialization. Left: 
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Haematoxylin and eosin stained cross-sections of wound centre. Scale bar 500 µM Arrows indicate the 
wound edges. Middle: Enlargement of the boxed section in the previous panel. Arrow-heads indicate 
new hair follicles in the wound bed. Scale bar 500 µM Right: Cross sections of wound centre were 
stained with Keratin 14 (green), α-SM actin (red) and DAPI (nuclei). Arrows indicate the initial wound 
site. Scale bar 90 µm. c) Effect of Tazarotene on new vessel formation in wound bed. Left, Cross 
sections of wounds were stained with CD31 (green), α-SM actin (red) and DAPI (nuclei). Scale bar 50 
µm. Right: CD31-positive microvessel area was quantified as a percentage of the wound bed area, n=6 
animals per group. Arrows indicate the wound edges. Unpaired-t-test, *p<0.05 compared to Vehicle 
group. 
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